GABA B receptors are the G-protein coupled receptors for the main inhibitory neurotransmitter in the brain, GABA. GABA B receptors were shown to associate with homo-oligomers of auxiliary KCTD8, KCTD12, KCTD12b, and KCTD16 subunits (named after their T1 K ϩ -channel tetramerization domain) that regulate G-protein signaling of the receptor. Here we provide evidence that GABA B receptors also associate with hetero-oligomers of KCTD subunits. Coimmunoprecipitation experiments indicate that two-thirds of the KCTD16 proteins in the hippocampus of adult mice associate with KCTD12. We show that the KCTD proteins hetero-oligomerize through selfinteracting T1 and H1 homology domains. Bioluminescence resonance energy transfer measurements in live cells reveal that KCTD12/ KCTD16 hetero-oligomers associate with both the receptor and the G-protein. Electrophysiological experiments demonstrate that KCTD12/KCTD16 hetero-oligomers impart unique kinetic properties on G-protein-activated Kir3 currents. During prolonged receptor activation (one min) KCTD12/KCTD16 hetero-oligomers produce moderately desensitizing fast deactivating K ϩ currents, whereas KCTD12 and KCTD16 homo-oligomers produce strongly desensitizing fast deactivating currents and nondesensitizing slowly deactivating currents, respectively. During short activation (2 s) KCTD12/KCTD16 hetero-oligomers produce nondesensitizing slowly deactivating currents. Electrophysiological recordings from hippocampal neurons of KCTD knock-out mice are consistent with these findings and indicate that KCTD12/KCTD16 hetero-oligomers increase the duration of slow IPSCs. In summary, our data demonstrate that simultaneous assembly of distinct KCTDs at the receptor increases the molecular and functional repertoire of native GABA B receptors and modulates physiologically induced K ϩ current responses in the hippocampus.
Introduction
GABA B receptors are the G-protein coupled receptors (GPCRs) for the inhibitory neurotransmitter GABA. GABA B receptors are expressed throughout the brain and influence synaptic transmission by regulating the activity of ion channels and adenylate cyclases (Couve et al., 2000; Chalifoux and Carter, 2011; . Postsynaptic GABA B receptors activate inwardly rectifying K ϩ channels (Kir3; also known as G-proteinactivated inwardly rectifying K ϩ channels [GIRK] ) that generate slow IPSCs (sIPSCs) (De Koninck and Mody, 1997; Lüscher et al., 1997; Lüscher and Slesinger, 2010; Booker et al., 2013) . GABA B receptors comprise principal and auxiliary subunits that assemble into molecularly and functionally distinct receptor subtypes (Schwenk et al., 2010 (Schwenk et al., , 2016 . The principal subunits GABA B1a , GABA B1b , and GABA B2 are seven-transmembrane proteins and generate fully functional heterodimeric GABA B(1a,2) and GABA B(1b,2) receptors (Möhler and Fritschy, 1999; Monnier et al., 2011) . The auxiliary subunits KCTD8, KCTD12, KCTD12b, and KCTD16 (herein collectively referred to as KCTDs) are cytosolic proteins that bind as homo-tetramers (Schwenk et al., 2010; Correale et al., 2013) or homo-pentamers (Smaldone et al., 2016) to the GABA B2 subunit (Bartoi et al., 2010; Schwenk et al., 2010) . KCTD8, KCTD12, KCTD12b, and KCTD16 comprise a clade of a larger family of KCTD proteins that all contain a T1 domain, which in voltage-gated K ϩ channels mediates tetramerization (Liu et al., 2013; Skoblov et al., 2013) . The T1 domain of the KCTDs interacts with the C-terminal intracellular domain of the GABA B2 subunit, in which tyrosine-902 (Y902) is mandatory for interaction (Schwenk et al., 2010; Correale et al., 2013) . The KCTDs additionally contain a conserved H1 homology domain, which in KCTD12 induces a pronounced desensitization of the GABA B receptor response by uncoupling the ␤␥ subunits of the activated G-protein from the effector channel . Selectively KCTD8 and KCTD16 feature a conserved H2 homology domain that prevents the receptor desensitization induced by the H1 domain .
The KCTDs exhibit overlapping expression patterns in the brain (Schwenk et al., 2010; Metz et al., 2011; Hayasaki et al., 2012) and, in principle, could form hetero-oligomers in various neuronal populations. Here we demonstrate that KCTD12 and KCTD16 indeed form hetero-oligomers through self-association of their T1 and H1 domains. KCTD12/KCTD16 hetero-oligomers directly bind to the receptor-associated G-protein and confer unique desensitization and deactivation kinetics to GABA B receptor-induced K ϩ currents. In hippocampal neurons, KCTD12/KCTD16 hetero-oligomers increase the duration of GABA B receptor-induced sIPSCs. In summary, our data show that KCTD hetero-oligomers contribute to functionally distinct GABA B receptor responses in the brain.
Materials and Methods
Mice. Kctd12 Ϫ/ Ϫ (RRID:MGI:5756048) and Kctd16 Ϫ/ Ϫ knock-out mice and control littermates of either sex were generated as described previously (Metz et al., 2011; Cathomas et al., 2015) . Kctd12/16 Ϫ/ Ϫ double knock-out mice of either sex were obtained from mating of Kctd12 Ϫ/ Ϫ and Kctd16 Ϫ/ Ϫ mice. All experiments with mice were subjected to institutional review and approved by the Veterinary Office of Basel-Stadt.
Cell lines and cultured hippocampal neurons. Human Embryonic Kidney 293 (HEK293) cells were from ATCC (RRID: CVCL_0045) and maintained in DMEM supplemented with GlutaMAX (Invitrogen ) and 10% FCS in a humidified atmosphere (5% CO 2 ) at 37°C. CHO-K1 cells (RRID: CVCL_0214), stably expressing human GABA B1b and rat GABA B2 (Urwyler et al., 2001) were maintained in DMEM with 500 M L-glutamine, 40 g/ml L-proline, 0.5 mg/ml G418, 0.25 mg/ml zeocine, and 10% FCS. Cells were transfected at 70%-90% confluency in 6-or 24-well plates or in 10 cm dishes using Lipofectamine 2000 (Invitrogen), X-tremeGENE (Roche), or polyethylenimine (Sigma). Cultured hippocampal neurons were prepared as described previously (Brewer et al., 1993; Biermann et al., 2010) . Briefly, embryonic day 16.5 mouse hippocampi were dissected, digested with 0.25% trypsin (Invitrogen) in 1 ϫ PBS solution for 15 min at 37°C, dissociated by trituration, and plated on glass coverslips coated with 1 mg/ml poly-L-lysine hydrobromide (Sigma) in 0.1 M borate buffer (boric acid/sodium tetraborate). Neurons were seeded at a density of ϳ550 cells/mm 2 in neurobasal medium (Invitrogen ) supplemented with B27 (Invitrogen) and 0.5 mM L-glutamine and cultured in a humidified atmosphere (5% CO 2 ) at 37°C. Cultured hippocampal neurons were transfected at DIV7.
Biochemistry. Plasmids used for biochemistry experiments encoding FLAG-and Myc-tagged KCTD10, KCTD8, KCTD12, and KCTD16 constructs were described previously . pCI-HA-GABA B2 -eYFP was a gift from Novartis.
Adult mouse brains were homogenized and lysed in 5 ml NETN buffer (100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 20 mM Tris/HCl, pH 7.4) supplemented with complete EDTA-free protease inhibitor mixture (Roche) using a Dounce homogenizer. Following rotation for 3 h at 4°C, brain lysates were cleared by centrifugation at 15,000 ϫ g for 30 min at 4°C. For affinity-depletion experiments, hippocampi of adult mouse brains were dissected and placed in 100 mg/ml of ice-cold homogenization medium (320 mM sucrose, 4 mM HEPES, pH 7.5, 1 mM EDTA, 1 mM EGTA, supplemented with complete EDTA-free protease inhibitor mixture) and homogenized using a glass-Teflon homogenizer with 20 passes on ice. After homogenization, the material was cleared by centrifugation at 1000 ϫ g (4°C, 15 min). The membrane-enriched fraction was isolated by ultracentrifugation at 48,000 ϫ g (4°C, 45 min) and solubilized for 3 h at 4°C in NETN buffer at 2 mg protein/ml. The solubilized fraction was cleared by ultracentrifugation at 10 5 ϫ g (4°C, 45 min). Cultured HEK293 cells were lysed 48 h after transfection in NETN buffer or modified RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, complete EDTA-free protease inhibitors, pH 7.4) by rotating for 30 min at 4°C. HEK293 cell lysates were then cleared by centrifugation at 10,000 ϫ g for 20 min at 4°C. Brain and cell lysates were directly used for immunoblot analysis (input lanes) or immunoprecipitated with guinea-pig anti-KCTD12 (RRID:AB_2631051), guinea-pig anti-KCTD16 (RRID: AB_2631053), or mouse anti-Myc (9E10, Santa Cruz Biotechnology, RRID: AB_627268) antibodies coupled to a mixture of protein-A and protein-G Sepharose (GE Healthcare). Lysates and immunoprecipitates were resolved using SDS-PAGE and probed with the primary antibodies rabbit anti-KCTD12 (1:2500, RRID:AB_2631049), rabbit anti-KCTD16 (1:2500, RRID:AB_2631050), rabbit anti-Myc (C3956, Sigma, 1:2500, RRID:AB_439680), rabbit anti-FLAG (F7425, Sigma, 1:2500, RRID:AB_439687), rabbit anti-GABA B2 (C44A4, #4819, Cell Signaling Technology, 1:1500, RRID:AB_2108339), and mouse ␤-tubulin III (T8660, Sigma, 1:2000, RRID:AB_477590) in combination with peroxidase-coupled secondary antibodies goat anti-guinea pig (A7289, Sigma, 1:10,000, RRID:AB_258337), sheep anti-mouse (NA931, GE Healthcare, 1:10,000, RRID:AB_772210), or donkey anti-rabbit (NA934, GE Healthcare, 1:10,000, RRID:AB_772206). Guinea-pig and rabbit KCTD12 and KCTD16 antibodies were raised against synthetic peptides of mouse KCTD12 (amino acid residues 145-167) or KCTD16 (residues 7-23) (Metz et al., 2011) . Chemiluminescence was detected using the SuperSignal West kit (Thermo Scientific).
Bimolecular luminescence protein-fragment complementation (BiLC), bimolecular fluorescence complementation (BiFC), and bioluminescence resonance energy transfer (BRET) assays. The BiLC and BiFC template constructs were published previously (Héroux et al., 2007; Stefan et al., 2007) . GATEWAY technology was used to insert the human KCTD cDNA C-terminal to Rluc and Venus fragments contained in a destination vector for eukaryotic expression based on pcDNA3.1(ϩ)/Zeo (Invitrogen): N-terminal (amino acids 1-110, NTRluc) and C-terminal (amino acids 111-311, CTRluc) fragments of a bright Renilla luciferase mutant RlucII (A55T/C124A/M185V-Rluc) and N-terminal (amino acids 1-154, NTVen) and C-terminal (amino acids 146 -239, CTVen) fragments of Venus. The construction of pcDNA3.1-Myc-GABA B1 and pcDNA3.1-HA-GABA B2 -GFP was reported previously (Villemure et al., 2005) . The GFP used for HA-GABA B2 -GFP is a blue-shifted GFP known as GFP10 that is a preferred acceptor in BRET2 assays (Mercier et al., 2002) . The HA and Myc tags were used to control for protein cell surface expression. The FLAG-G␤2 and Venus-G␥2 constructs used for BRET experiments were reported previously Rajalu et al., 2015) .
For BiLC, BiFC, and BRET assays, HEK293 cells were harvested 48 h after transfection, suspended in PBS, and distributed into 96-well microplates at 1-3 ϫ 10 5 cells/well. To measure reconstituted luciferase activity from BiLC proteins, the luciferase substrate coelenterazine h (Nanolight Technology, final concentration 5 M) was added to each well and luminescence signals were measured 2 min later using a Mithras LB940 multimode plate reader (Berthold Technologies). The expression levels of fluorescent proteins were measured using a FlexStation 2 fluorimeter (Molecular Devices) with excitation and emission wavelengths set at 410 and 510 nm (GFP10) or 518 and 570 nm (Venus), respectively. BRET2 between KCTD-BiLC and GABA B2 -GFP was measured 2 min after addition of the luciferase substrate DeepBlue C (coelenterazine 400A; Nanolight Technology; final concentration of 5 M). BRET was calculated as the ratio of the light emitted by GFP10 (515 Ϯ 20 nm) over the light emitted by RlucII (400 Ϯ 70 nm) using a Mithras LB940 luminometer. The net BRET signal was defined as the difference between the total BRET and the signal obtained from samples expressing the RlucII-fusion constructs alone (background signal), and plotted against the ratio between the expression levels of the GFP10-and RlucII-fusion constructs as measured by the total fluorescence and luminescence signals, respectively, as previously described (Mercier et al., 2002) . BRET between KCTD-BiLC and KCTD-BiFC was measured 2 min after the addition of the luciferase substrate, coelenterazine h (final concentration of 5 M). BRET was calculated as the ratio of the light emitted by Venus (530 Ϯ 20 nm) over the light emitted by RlucII (480 Ϯ 20 nm) using a Mithras LB940 luminometer. BRET signals between KCTD-BiLC and Venus-G␥2 were measured on an Infinite F500 microplate reader (Tecan) detecting Venus at 550 Ϯ 25 nm and RlucII at Ͻ475 nm.
Electrophysiology. Whole-cell patch-clamp recordings of GABA Bmediated Kir3 currents from CHO cells and cultured hippocampal neurons were performed 48 -72 h and ϳ2 weeks (DIV18-DIV21) after transfection, respectively. EGFP-expressing cells were identified via epifluorescence using an FITC filter set and patched under infrared oblique illumination (BX61WI; Olympus). Kir3 currents were recorded at room temperature (22°C-23°C) in aCSF containing the following (in mM): 145 NaCl, 2.5 KCl, 1 MgCl 2 , 2 CaCl 2 , 10 HEPES, 25 glucose, pH 7.3. Neurons were superfused with aCSF supplemented with TTX (0.5 M), DNQX (10 M), and picrotoxin (100 M). Patch electrodes were pulled from borosilicate glass capillaries (resistance of 3-5 M⍀) and filled with a solution containing the following (in mM): 107.5 K-gluconate, 32.5 KCl, 10 HEPES, 5 EGTA, 4 Mg-ATP, 10 phosphocreatine, 0.6 Na 2 -GTP, at pH 7.2 (adjusted with KOH), 292 mOsm. GABA B receptor responses were evoked at Ϫ50 mV by fast application of baclofen (100 M, 1-60 s) Dittert et al., 2006) .
IPSCs were recorded in parasagittal hippocampal slices prepared from P25-P30 mice as follows. Animals were decapitated and the brains were excised in ice-cold extracellular solution containing the following (in mM): 130 NaCl, 3.5 KCl, 3.0 MgCl 2 , 0.5 CaCl 2 , 10 glucose, 1.25 NaH 2 PO 4 , 25 NaHCO 2 , 0.5 ascorbic acid, 3 myo-inositol, and 3 sodium pyruvate; gassed with 5% CO 2 /95% O 2 to pH 7.3. Slices (300 m thick) were cut using a VT1200S vibratome (Leica), incubated at 35°C for 45 min and then stored at 31°C-32°C in the extracellular solution in which the concentrations of MgCl 2 and CaCl 2 were 1 and 2 mM, respectively. For recording, slices were superfused with aCSF containing the following (in mM): 130 NaCl, 3.5 KCl, 1.5 MgCl 2 , 1.5 CaCl 2 , 10 glucose, 1.25 NaH 2 PO 4 , 24 NaHCO 3 , pH 7.3, equilibrated with 5% CO 2 /95% O 2 . IPSCs were elicited by electric stimulation of stratum radiatum via bipolar electrode and isolated in the presence of DNQX (10 M), CPP (5 M), and SR95531 (gabazine; 15 M, used for recording of sIPSCs). Patch pipette solution contained the following (in mM): 107.5 K-gluconate, 32.5 KCl, 10 HEPES, 0.1 EGTA, 4 Mg-ATP, 10 phosphocreatine, 0.6 Na 2 -GTP, at pH 7.2, 290 mOsm. Pharmacological GABA B responses or IPSCs were acquired with an Axopatch 200B low-pass filtered at 1 or 5 kHz and digitized at 5 or 20 kHz using a Digidata 1440A interface (Molecular Devices) driven by pClamp 10 software (RRID:SCR_011323). Cell capacitance was calculated using membrane time-constant and cell resistance values obtained from voltage responses of cells upon applying hyperpolarizing Ϫ10 pA steps at the resting potential. The holding potential was adjusted for a measured liquid junction potential of 12 mV. Whole-cell currents and voltages were analyzed using Clampfit 10 software (Molecular Devices). All values are given as mean Ϯ SD. Statistical significances were tested using one-way ANOVA or Student's t test (GraphPad Prism, RRID:SCR_002798). TTX was from Latoxan. DNQX, CPP, and SR95531 were from Tocris Bioscience. All other reagents were from Sigma-Aldrich.
Results

KCTD hetero-oligomers in the brain
We used immunoprecipitation (IP) experiments to address whether KCTD hetero-oligomers exist in the brain (Fig. 1A) . We limited our analysis to KCTD12 and KCTD16, which in the adult brain are coexpressed in many neuronal populations, including hippocampal pyramidal neurons (Metz et al., 2011) . We found that anti-KCTD12 antibodies copurified KCTD16 protein from wild-type (WT) but not from control KCTD12 knock-out (Kctd12 Ϫ/ Ϫ ) brain lysates ( Fig. 1A) . Reverse IP experiments with anti-KCTD16 antibodies confirmed the existence of KCTD12/ KCTD16 hetero-oligomers in WT but not in control Kctd16 Ϫ/ Ϫ brain lysates ( Fig. 1A) .
We next depleted KCTD12 from hippocampal lysates to determine the fraction of KCTD16 protein participating in KCTD12/KCTD16 hetero-oligomers. Complete depletion of KCTD12 from lysates with specific anti-KCTD12 antibodies removed 64.9 Ϯ 6.1% (n ϭ 3) of the KCTD16 protein from the supernatant (Fig. 1B) . In the hippocampus, approximately twothirds of the KCTD16 protein is therefore associated with KCTD12. For unknown reasons, anti-KCTD16 antibodies inefficiently depleted KCTD16 from hippocampal lysates, which pre- Figure 1 . KCTD hetero-oligomers are abundant in the adult mouse brain. A, Anti-KCTD12 and anti-KCTD16 antibodies (Schwenk et al., 2010) copurify KCTD12 and KCTD16 proteins in immunoprecipitation (iP) experiments with brain lysates of WT mice, as shown on immunoblots (IB). Control IPs with brain lysates of Kctd12 Ϫ/ Ϫ and Kctd16 Ϫ/ Ϫ mice (Metz et al., 2011) show that the antibodies are specific for the KCTD12 and 16 proteins. Asterisks indicate cross-reactions of the anti-KCTD16 antibody in the Input samples. B, Affinity depletion of KCTD12 from hippocampi of adult mouse brains using anti-KCTD12 antibodies leads to a codepletion of KCTD16 engaged in KCTD12/KCTD16 hetero-oligomers (depleted). Control IBs of ␤-tubulin III show that the neuron-specific marker protein is not depleted by anti-KCTD12 antibodies.
vented a meaningful assessment of the fraction of KCTD12 protein involved in KCTD12/KCTD16 hetero-oligomers.
T1 and H1 domains mediate homo-and hetero-oligomerization
The KCTDs are modular proteins consisting of an N-terminal T1 tetramerization domain and one or two C-terminal H1 and H2 homology domains ( Fig. 2A) . Earlier experiments supported that the T1 domain of KCTD12 forms homo-oligomers (Schwenk et al., 2010; Smaldone et al., 2016) . To study whether the KCTDs form hetero-oligomers in transfected HEK293 cells, we performed co-immunoprecipitation experiments with FLAG-and Myc-tagged KCTD proteins. We included KCTD10, which belongs to a different clade of the KCTD family , into our analysis. KCTD10 does not associate with GABA B receptors (Schwenk et al., 2010) and lacks H1 and H2 domains ( Fig.  2A ). We found that KCTD8, KCTD10, KCTD12, and KCTD16 assemble homooligomers in HEK293 cells (Fig. 2B) ; however, only KCTD8, KCTD12, and KCTD16 form hetero-oligomers in all possible dual combinations (Fig. 2C) .
IP experiments with the isolated Myctagged T1, H1 or H2 domains of KCTD12 and KCTD16 show that both the T1 and H1 domains interact with FLAG-tagged KCTD12 ( (Fig. 3B ). Collectively, these results indicate that both the T1 and H1 domains mediate KCTD homo-and hetero-oligomerization. Consistent with the H1 domains mediating oligomerization, Myc-16⌬T1, a KCTD16 mutant lacking the T1 domain, still forms homo-oligomeric FLAG-KCTD16/Myc-16⌬T1 ( Fig. 3 B, C) and hetero-oligomeric FLAG-KCTD12/ Myc-16⌬T1 complexes (Fig. 3A,B ) that interact with GABA B2 through the T1 domain of the full-length KCTD in the complex (Fig. 3C ).
Detection of KCTD homo-and hetero-oligomers in live cells
We next used a bimolecular luminescence protein-fragment complementation (BiLC) assay (Stefan et al., 2007; Armando et al., 2014) to study KCTD oligomerization in live cells. KCTD proteins were tagged at their N termini with the N-or C-terminal fragment of Renilla luciferase (NTRluc and CTRluc). In such a way, oligomerization of KCTD protomers can be quantified by measuring the activity (luminescence) of reconstituted Rluc. The Rluc activity measured in transfected HEK293 cells indicates that KCTD10, KCTD12, and KCTD16 all form homo-oligomers ( Fig. 4A ). KCTD12 and KCTD16 additionally form hetero-oligomers with each other (Fig. 4A) . A 100-fold lower level Rluc activity was observed with KCTD10 in combination with KCTD12 or KCTD16 (Fig. 4A ). This may represent weak nonspecific luciferase reconstitution/activity or indicate a very low level of hetero-oligomerization. KCTD homo-oligomer formation also promotes bimolecular fluorescence complementation (BiFC) Héroux et al., 2007) of Venus (Fig. 4A ), a variant of the yellow fluorescent protein that can be used as an energy acceptor in BRET experiments. Of note, we were unable to detect a specific BiFC signal for KCTD16 homo-oligomers, suggesting that KCTD16 protomers have a lower propensity to form homo-oligomers. This is supported by two-component BRET assays using KCTD-RlucII and KCTD-GFP2 constructs, in which KCTD12 homo-oligomers showed ϳ9 times lower half BRET saturation values than KCTD16 homo-oligomers (KCTD12: 0.064, and KCTD16: 0.56). BiFC of Rluc and Venus allowed us to investigate whether reconstitution of Rluc and Venus from their Nand C-terminal fragments fused to KCTD monomers yields BRET due to the formation of KCTD oligomers made up from at least four protomers. Expression of increasing amounts of NTVen12 ϩ CT-Ven12 with fixed amounts of NTRluc12 ϩ CTRluc12 resulted in a hyperbolic BRET donor saturation curve (Fig. 4B) , consistent with the assembly of KCTD12 homo-tetramers (or homo-pentamers) in live cells. The complementation experiments support a parallel arrangement of KCTD subunits in the oligomers. Expression of NTRluc12 ϩ CTRluc12 or NT-Ven10 ϩ CTVen10 with increasing amounts of NTVen10 ϩ CTVen10 or NTRluc12 ϩ CTRluc12, respectively, did not yield clearly saturating BRET donor curves (Fig. 4B) . Inefficient complementation of Venus by NTVen16 ϩ CTVen16 (Fig. 4A) prevented us from testing with BiFC/BRET whether KCTD16 homo-and KCTD12/KCTD16 hetero-tetramers are formed.
KCTD12/KCTD16 hetero-oligomers interact with the receptor and the G-protein
We used BiLC in combination with BRET to study whether KCTD hetero-oligomers interact with GABA B receptors in intact cells. BRET-donor saturation curves were determined with fixed amounts of NTRlucKCTDs ϩ CTRlucKCTDs and increasing amounts of Myc-GABA B1 and the energy acceptor HA-GABA B2 -GFP (Fig. 5A) . We observed specific BRET between the reconstituted Rluc and HA-GABA B2 -GFP with KCTD12 and KCTD16 homo-oligomers as well as with KCTD12/KCTD16 heterooligomers. We did not observe specific BRET with KCTD10 homo-oligomers and the receptor, as indicated by low BRET and a nonsaturating BRET to acceptor/donor relationship (Fig. 5A) . Similarly, a nonspecific BRET signal with a linear BRET to acceptor/donor relationship ( y ϭ 2.4 x ϩ 5.7) was obtained in control experiments with KCTD12 homo-oligomers and a GABA B2 acceptor in which tyrosine-902 was mutated to alanine, which prevents KCTD binding to GABA B2 (Schwenk et al., 2010) . BRET experiments therefore demonstrate that KCTD12/KCTD16 hetero-oligomers interact with GABA B receptors in live cells.
The KCTDs not only interact with the receptor but also with the G-protein . It is unknown whether the KCTDs interact as monomers or oligomers with the G-protein.
We therefore used BiLC in combination with BRET to study whether KCTD oligomers can interact with the G-protein. We determined BRET donor saturation curves using fixed amounts of NTRlucKCTDs ϩ CTRlucKCTDs and increasing amounts of the G-protein subunits G␤2 and Venus-G␥2 (Fig. 5B) . BRET between the reconstituted Rluc and Venus-G␥2 was observed with KCTD12 and KCTD16 homo-oligomers as well as with KCTD12/KCTD16 hetero-oligomers. Because KCTD12 and KCTD16 exert distinct kinetic effects on G-protein signaling (Schwenk et al., 2010; , it is possible that KCTD hetero-oligomers endow receptors with novel properties. studied the influence of hetero-oligomeric KCTD12/KCTD16 complexes on K ϩ current desensitization in transfected CHO cells expressing GABA B receptors together with Kir3 channels. We recorded K ϩ currents in response to a prolonged application of the GABA B agonist baclofen (100 M, 1 min). Cells coexpressing KCTD12 and KCTD16 exhibited significantly reduced and slower K ϩ current desensitization than cells expressing KCTD12 alone ( Fig. 6 A, C,E) . This may be due to the formation of heterooligomeric KCTD12/KCTD16 complexes and/or the simultaneous assembly of desensitizing KCTD12 and nondesensitizing KCTD16 homo-oligomers. To avoid association of KCTD16 homo-oligomers with the receptor, we substituted KCTD16 with 16⌬T1, which lacks the T1 domain that is necessary for direct binding to the receptor (Schwenk et al., 2010). However, 16⌬T1 is able to indirectly bind to the receptor through heterooligomerization with KCTD12 ( Fig. 3C ). Cells expressing KCTD12 and 16⌬T1 therefore form receptors associated with KCTD12/KCTD16⌬T1 hetero-oligomers or KCTD12 homooligomers but not with 16⌬T1 homo-oligomers. We found that cells coexpressing 16⌬T1 and KCTD12 exhibited reduced and slower K ϩ current desensitization than cells expressing KCTD12 alone ( Fig. 6B-E) , which demonstrates that the kinetic properties of KCTD12/KCTD16⌬T1 hetero-oligomers differ from those of KCTD12 homo-oligomers. As a control, expression of 16⌬T1 alone yielded nondesensitizing responses ( Fig. 6 B, C) , similar to expression of KCTD16 alone ( Fig. 6 A, B) . In summary, the electrophysiological data indicate that KCTD12/KCTD16 heterooligomers desensitize GABA B -activated K ϩ currents to a lesser extent and more slowly than KCTD12 homo-oligomers.
Analysis of the deactivation kinetics of K ϩ currents activated by applying baclofen for 1 min revealed a novel regulatory feature of the KCTDs (Fig. 6 F, G) . KCTD12 and KCTD16 significantly accelerated and slowed current deactivation, respectively, compared with cells lacking KCTDs (Fig. 6 F, G) . A slowing of current deactivation is also observed with 16⌬T1 ( Fig. 6 F, G) . This indicates that the deactivation does not necessarily require KCTD16 binding to the receptor and supports that the deactivation mechanism operates downstream of the receptor. Coexpression of KCTD12 with 16⌬T1 or KCTD16 yielded fast deactivating currents, showing that KCTD12 overrules the slowing effect of 16⌬T1 or KCTD16 within the hetero-oligomer (Fig. 6 F, G) . No accelerated current deactivation is observed in the presence of KCTD12 after a baclofen application for 2 s, which is too short to induce pronounced desensitization ( Fig. 6 H, I ) . Accelerated cur- B, BRET between reconstituted Rluc and Venus in KCTD oligomers. Cells were transfected with fixed amounts of NTRlucKCTD and CTRlucKCTD constructs and increasing amounts of NTVenKCTD and CTVenKCTD constructs. BRET donor saturation curves were generated by expressing the net BRET signal detected as a function of the ratio between the total fluorescence signal and the luminescence signal (acceptor/donor ratio; expressed in milliBRET units, mBU) and demonstrate that both KCTD12 and KCTD10 can assemble into homo-tetramers or higher-order oligomers from the individually tagged monomers. KCTD12 and KCTD10 have a much weaker propensity to form hetero-tetramers. Data points represent the mean of technical duplicates combined from 4 independent experiments. rent deactivation in the presence of KCTD12 thus correlates with current desensitization. This is corroborated by a similar baclofen concentration dependence of current desensitization and deactivation in the presence of KCTD12 (Fig. 7A ). We did not observe a sigmoidal agonist concentration dependence of current deactivation in the absence of KCTD or in the presence of KCTD16 (Fig. 7B) , which further supports that accelerated deactivation relates to KCTD12-induced desensitization. The slowing of current deactivation that is observed in the presence of KCTD16 (Fig. 6G) is use-dependent, as indicated by the linear baclofen concentration dependence of the deactivation (Fig. 7B) . In summary, the data show that, after prolonged receptor activation, homo-oligomeric KCTD12 complexes yield strongly desensitizing fast deactivating K ϩ current responses. In contrast, homo-oligomeric KCTD16 complexes yield nondesensitizing slowly deactivating current responses. Hetero-oligomeric KCTD12/ KCTD16 complexes produce distinct current K ϩ responses characterized by intermediate desensitization and fast deactivation. In contrast, during brief receptor activation, KCTD12/KCTD16 hetero-oligomers produce nondesensitizing slowly deactivating current responses.
We observed that individual and combined expression of KCTD12 and KCTD16 in transfected CHO cells significantly increases the peak K ϩ current amplitudes (presented as current densities) in response to a nearly saturating concentration of baclofen (Fig. 7C) . No increase in current density is observed with 16⌬T1, which does not bind to the receptor (Fig. 7C) . The increase in current density observed with KCTD12, KCTD16, and KCTD12/KCTD16 may therefore relate to precoupling of the G-protein at the receptor via the KCTD proteins Schwenk et al., 2016) . Increased surface expression of GABA B receptors in the presence of KCTD12 (Ivankova et al., 2013) may further contribute to an increase in current amplitude. Receptors assembled with KCTD12/KCTD16⌬T1 show a trend toward increased current amplitudes, which, however, does not reach statistical significance (Fig. 7C) . Possibly, precoupling of the G-protein and/or surface expression is less efficient when KCTD12 combines with 16⌬T1 than with full-length KCTD16.
We additionally determined the baclofen concentration/K ϩ current response curves in the presence or absence of KCTD12 and KCTD16. The EC 50 values (derived from log(baclofen)/K ϩ current response) measured in CHO cells expressing KCTD12 (9.7 Ϯ 7.7 M, n ϭ 8) or KCTD16 (20.8 Ϯ 8.7 M, n ϭ 7) were significantly smaller than those in cells lacking KCTD proteins (66.4 Ϯ 26.7 M, n ϭ 8; p Ͻ 0.001, Dunnett's multiplecomparison test), consistent with earlier findings (Schwenk et al.,  2010) . The EC 50 values measured in cells expressing KCTD12 or KCTD16 do not significantly differ from each other (Bonferroni , with KCTD12 alone (black), with KCTD16 alone (blue), or with both KCTDs (red). KCTD12, but not KCTD16, induces pronounced and rapid desensitization of K ϩ currents. Coexpression of KCTD12 and KCTD16 results in intermediate current desensitization. B, Baclofen-activated K ϩ currents recorded from CHO cells either expressing KCTD12 (black), a KCTD16 mutant lacking the T1 domain (16⌬T1, blue), or both KCTD isoforms (red). Expression of KCTD12 together with 16⌬T1, which only binds to the receptor in a complex with KCTD12, reduces KCTD12-induced desensitization. C, Bar graph summarizing the relative desensitization of baclofen-activated K ϩ currents. The relative desensitization was calculated as follows: (1 Ϫ (ratio of current amplitude after 60 s vs peak current)) ϫ 100. Values are mean Ϯ SD of 26 (w/o KCTD), 17 (KCTD12), 14 (KCTD16), 11 (16⌬T1), 6 (KCTD12/KCTD16), and 13 (KCTD12/KCTD16⌬T1) cells. D, Normalized traces represent a slower time course of K ϩ current desensitization in CHO cells coexpressing KCTD12 and 16⌬T1 (red) compared with CHO cells expressing KCTD12 alone (black). Traces are fitted to a double exponential function (gray solid line) with time constants 1 ϭ 1.0 s (relative contribution to desensitization 71.7%) and 2 ϭ 9.4 s for KCTD12 and 1 ϭ 3.9 s (33.8%) and 2 ϭ 28.4 s for KCTD12/KCTD16⌬T1. E, Bar graph showing mean amplitude-weighted time constants obtained from fits of a double exponential function to K ϩ current deactivation. F, Superimposed traces of the deactivation phase of K ϩ currents activated by application of baclofen to CHO cells for 1 min as in A or B displayed with an expanded time scale. KCTD12 and KCTD16 have opposite effects on the time course of the deactivation, with KCTD12 being dominant when (Figure legend continues.) pairwise comparison test). Because the KCTD proteins have marginal effects on agonist affinity at the orthosteric binding site (Rajalu et al., 2015) , the decrease in EC 50 values in the presence of KCTD12 or KCTD16 is best explained by the KCTD-mediated precoupling of the G-protein at the receptor Schwenk et al., 2016) . KCTD hetero-oligomers and homooligomers therefore likely activate G-proteins to a similar extent.
KCTD12/KCTD16 hetero-oligomers regulate GABA B -activated K ؉ currents in hippocampal neurons
We next investigated whether KCTD hetero-oligomers influence baclofen-activated K ϩ currents in cultured neurons. Previous experiments showed that hippocampal neurons express high levels of KCTD12 and KCTD16 (Schwenk et al., 2010; Metz et al., 2011) and that the lack of KCTDs in knock-out neurons influences desensitization of baclofen-evoked K ϩ currents . Accordingly, we found that, during prolonged receptor activation, K ϩ currents desensitize significantly less in Kctd12 Ϫ/ Ϫ and Kctd12/16 Ϫ/ Ϫ neurons than in WT neurons, as expected from the lack of KCTD12 ( Fig. 8 A, B) . When directly comparing Kctd12 Ϫ/ Ϫ and Kctd12/16 Ϫ/ Ϫ neurons, we observe significantly less desensitization in Kctd12/16 Ϫ/ Ϫ neurons than in Kctd12 Ϫ/ Ϫ neurons (Fig. 8B) . Desensitization is activitydependent and therefore influenced by the kinetic properties of the G-protein activation/deactivation cycle (i.e., the rates of GDP-GTP exchange and GTP hydrolysis at G␣) (Chuang et al., 1998; Leaney et al., 2004) . Less desensitization in Kctd12/16 Ϫ/ Ϫ than in Kctd12 Ϫ/ Ϫ neurons may thus be caused by reduced precoupling of the G-protein at the receptor and a consequent slower K ϩ current activation. K ϩ currents displayed significantly increased desensitization in Kctd16 Ϫ/ Ϫ neurons versus WT neurons. Considering that two-thirds of the KCTD16 proteins in the hippocampus are associated with KCTD12 (Fig. 1B) , the increased desensitization in Kctd16 Ϫ/ Ϫ neurons can be explained by the absence of KCTD12/KCTD16 complexes that normally would attenuate KCTD12-induced desensitization. In line with this proposal, expression of exogenous KCTD16 or 16⌬T1 in Kctd16 Ϫ/ Ϫ neurons significantly decreased desensitization (Fig.  8C,D) , which in the case of 16⌬T1 must relate to oligomerization with endogenous KCTD12. In addition to forming heterooligomers with endogenous KCTD12, exogenous KCTD16 may additionally compete with endogenous KCTD12 for binding at the receptor, which further decreases desensitization. K ϩ current deactivation was significantly slowed in Kctd12 Ϫ/ Ϫ neurons compared with WT neurons (Fig. 8 E, F ) , in line with a faster K ϩ current deactivation observed during prolonged baclofen application in the presence of KCTD12 in transfected CHO cells (Fig. 6F,G) . The significantly slower current deactivation in Kctd12 Ϫ/ Ϫ compared with Kctd12/16 Ϫ/ Ϫ neurons ( Fig. 8 E, F ) is also consistent with the observed slowing of current deactivation in CHO cells expressing KCTD16 (Fig. 6G) . We also observed a slowing of current deactivation when overexpressing exogenous KCTD16 in Kctd16 Ϫ/ Ϫ neurons (Fig. 8F ). In this case, overexpression of exogenous KCTD16 may outcompete endogenous KCTD12 (that accelerates deactivation) at the receptor. In contrast, no slowing of K ϩ current deactivation is observed when overexpressing exogenous 16⌬T1 in Kctd16 Ϫ/ Ϫ neurons, presumably because 16⌬T1 does not compete with endogenous KCTD12 for binding at the receptor. This result is consistent with results obtained in heterologous cells showing that coexpression of KCTD12 with 16⌬T1 produces similar deactivation kinetics as KCTD12 alone during prolonged baclofen application (Fig. 6F,G) . Therefore, it appears that KCTD12 dictates the deactivation kinetics in KCTD12/KCTD16⌬T1 hetero-oligomers. In summary, the analysis of hippocampal neurons supports that the KCTD composition of GABA B receptors enables a bidirectional regulation of the desensitization and deactivation kinetics of receptor-activated K ϩ currents.
The current densities of baclofen-evoked K ϩ currents in Kctd12/Kctd16 Ϫ/Ϫ neurons were significantly reduced compared with WT, Kctd12 Ϫ/ Ϫ , and Kctd16 Ϫ/ Ϫ neurons (WT: 1.7 Ϯ 0.6 pA/pF, n ϭ 18; Kctd12 Ϫ/ Ϫ : 1.5 Ϯ 0.7 pA/pF, n ϭ 16, Kctd16 Ϫ/ Ϫ : 1.6 Ϯ 0.7 pA/pF, n ϭ 13, Kctd12/Kctd16 Ϫ/Ϫ : 1.0 Ϯ 0.3 pA/pF, n ϭ 13; p Ͻ 0.01; Dunnett's multiple-comparison test). This is consistent with the data from heterologous cells showing that KCTD12 and KCTD16 increase the peak amplitude of baclofen-induced K ϩ currents (Fig. 7C) .
Altered GABA B -mediated sIPSCs in Kctd16 ؊/؊ neurons The data presented above suggest that the KCTD composition influences the kinetics of sIPSCs during prolonged GABA B receptor activation (Mapelli et al., 2009; Wang et al., 2010) . However, whether the KCTD composition influences sIPSCs during phasic short receptor activation (De Koninck and Mody, 1997; Lüscher et al., 1997) is unclear. We therefore analyzed the decay of neuronal GABA B responses following a brief (1 s) pharmacological activation with baclofen ( Fig. 9A,B ). The deactivation of K ϩ currents in response to this brief baclofen stimulus is significantly faster in Kctd16 Ϫ/ Ϫ neurons compared with WT or Kctd12 Ϫ/ Ϫ neurons. This suggests that, in hippocampal neurons, KCTD16, but not KCTD12, influences the duration of GABA B receptor-induced phasic sIPSCs. To test whether KCTD16 indeed regulates the deactivation kinetics of synaptically evoked currents, we recorded sIPSCs elicited by electric stimulation of GABAergic fibers in the stratum radiatum from CA1 pyramidal neurons clamped at Ϫ50 mV (Fig. 9C) . Fitting of the sIPSC decay phase with a one exponential function revealed that the decay time constant was significantly reduced in Kctd16 Ϫ/ Ϫ neurons compared with WT neurons (Fig. 9C-E) . The maximal amplitude of sIPSCs (WT: 19.5 Ϯ 8.0 pA, n ϭ 8; Kctd16 Ϫ/Ϫ : 21.1 Ϯ 8.1 pA, n ϭ 8) and the decay phase of GABA A receptor-mediated IPSCs (Fig. 9 D, E) are not altered in Kctd16 Ϫ/Ϫ neurons. This makes it unlikely that the changes observed in sIPSC kinetics in Kctd16 Ϫ/Ϫ neurons are due to adaptive changes in GABA uptake or degradation. In Kctd12 Ϫ/Ϫ neurons, the deactivation kinetics of sIPSCs were similar to WT neurons while their maximal amplitudes were significantly reduced (WT: 24.6 Ϯ 9.1 pA, n ϭ 11; Kctd12 Ϫ/Ϫ : 16.8 Ϯ 7.4, n ϭ 11). The reduction in amplitude may relate to a decrease in receptor surface expression in the absence of KCTD12 (Ivankova et al., 2013) . In summary, we find that the kinetic properties of sIPSCs in hippocampal neurons are shaped by the KCTD16-mediated slowing of K ϩ current deactivation, an effect that is retained in hetero-oligomeric complexes with KCTD12.
Discussion
It is well established that KCTD homooligomers bind to GABA B receptors and regulate G-protein signaling of the receptor (Schwenk et al., 2010; Rajalu et al., 2015) . Here we demonstrate that KCTDs also form hetero-oligomers in all possible dual combinations. We further show that GABA B receptors assembled with KCTD12/KCTD16 hetero-oligomers combine regulatory properties of the individual KCTDs to generate receptors with novel signaling characteristics. In response to prolonged receptor stimulation for 1 min, KCTD12/KCTD16 hetero-oligomers produce moderately desensitizing fast deactivating currents whereas KCTD12 and KCTD16 homo-oligomers produce strongly desensitizing fast deactivating currents and nondesensitizing slowly deactivating currents, respectively. In response to brief receptor stimulation (2 s), hetero-oligomers produce nondesensitizing slowly deactivating currents. Accordingly, we show that, in hippocampal neurons, KCTD12/KCTD16 hetero-oligomers significantly slow the deactivation kinetics of phasic GABA B receptor-induced sIPSCs.
KCTD hetero-oligomers in the brain
Hetero-oligomerization of KCTD8, KCTD12, and KCTD16 is mediated by the self-interacting T1 and H1 homology domains that also mediate homo-oligomerization (Schwenk et al., 2010; Correale et al., 2013) . Hetero-oligomerization was observed within other KCTD clades (Sowa et al., 2009; De Smaele et al., 2011) . Based on our BiLC experiments we conclude that KCTD oligomers arrange in parallel, similar as with KCTD5 (Dementieva et al., 2009) . BiLC experiments are consistent with the proposed tetrameric or pentameric assembly of native KCTD oligomers (Schwenk et al., 2010; Correale et al., 2013; Smaldone et al., 2016) . Because many neurons in the brain simultaneously express several KCTDs and some possibly all KCTDs (Metz et al., 2011) , hetero-oligomers are expected to be abundant. In the hippocampus, we estimate that ap-proximately two-thirds of the KCTD16 proteins are involved in KCTD12/KCTD16 hetero-oligomers. The KCTDs assemble with GABA B receptors at the cytoplasmic side of the endoplasmic reticulum membrane (Ivankova et al., 2013). It is currently unknown whether KCTD hetero-oligomers assemble randomly or combine by a regulated process. 
